CELYAD ONCOLOGY SA

ISIN: **BE0974260896** Asset Class: Stock

Company

2024/07/16 17:35:12

Price

0.27 EUR

Difference • 0.37%(0.00)

Contact Details

CELYAD ONCOLOGY SA

Axis Business Park, Rue André

Dumont 9


1435 Mont-Saint-Guibert

Tel: +32-10-039-41-00 Fax: +32-10-039-41-41

Web:

http://www.celyad.com

E-mail: info@celyad.com



Company Profile

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20:	22	202	21
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	11,121,000		14,825,000		34,292,000	
Common stock capital		32,949,000		78,585,000		78,585,000
Fixed assets	5,161,000		4,891,000		45,651,000	
Equity capital of a company		-10,327,000		-12,314,000		27,008,000
Cash and cash equivalents	7,004,000		12,445,000		30,018,000	
Accrued liabilities		1,000		13,000		53,000
Other assets	-		-		-	
Current liabilities		2,932,000		10,426,000		13,827,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		23,677,000		21,604,000		39,108,000
Different income		-		-		-
Other liabilities		6,143,000		4,842,000		20,694,000
Total assets	16,282,000	16,282,000	19,716,000	19,716,000	79,943,000	79,943,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	17	39	103
Equity ratio	-63.43%	-62.46%	33.78%
Debt-equity ratio	-257.66%	-260.11%	196.00%

Others

	2023	2022	2021
Tax Expense Rate	2.21%	0.96%	2.49%

CELYAD ONCOLOGY SA

ISIN: BE0974260896 WKN: - Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	102,000	0	0
Net income	-8,448,000	-40,935,000	-26,512,000
EBIT	-8,587,000	-41,147,000	-26,961,000
Operating income before taxes	-8,639,000	-41,332,000	-27,189,000
Cash Flow	-15,202,000	-28,010,000	-26,643,000
Net interest income	-52,000	-185,000	-228,000
Research and development expenses	3,881,000	17,697,000	19,496,000
Income taxes	-191,000	-397,000	-677,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	6,000	0	0

Board of Directors	
Hilde Windels	Chairman of Supervisory Board
Marina Udier	Member of Supervisory Board
Ami Shah	Member of Supervisory Board
Andrea Gothing	Member of Supervisory Board
Dominic Piscitelli	Member of Supervisory Board
John LiPuma	Member of Supervisory Board
Jonathan James	Member of Supervisory Board
Sage Mandel	Member of Supervisory Board
Serge Goblet	Member of Supervisory Board

Members of Management Board		
Georges Rawadi	Chairman of Managing Board	
An Phan	Member of Executive Committee	
David Georges	Member of Executive Committee	
Eytan Breman	Member of Executive Committee	
Hannes Iserentant	Member of Executive Committee	